Engflag

Lactihep

Quick links to important sections

Lactihep

Lactihep_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactihep

Property Description
Active ingredient Lactitol Monohydrate, Benzoic Acid
Form Oral Solution (Syrup)
Pharmacological class Osmotic Laxative, Ammonium Detoxicant
General purpose Stool softening and ammonia level support
Origin Synthetic sugar derivative (Lactitol)

What Type of Medicine is Lactihep?

Lactihep is a prescription-only combination drug formulated as an Oral Solution or Syrup for administration via the oral route. It is classified primarily as an Osmotic Laxative and an Ammonium Detoxicant. This dual classification positions it as both a purgative agent and a crucial supportive treatment aimed at managing specific gastrointestinal and hepatic requirements. This pharmacological type utilizes basic physical principles to exert its effects locally within the digestive tract, distinguishing it from medications that act systemically.

As an Osmotic Laxative, the active component remains unabsorbed, exerting an osmotic pressure that draws water into the bowel. The medicine works by using the body’s own water to soften the stool, a function that serves to provide gentle and effective relief.

Composition and Origin of Lactihep

The active ingredient in Lactihep is Lactitol Monohydrate, a synthetic disaccharide sugar alcohol, which is the source of the therapeutic action. The formulation is completed by Benzoic Acid, a chemical preservative included to ensure the stability and safety of the Syrup by preventing microbial contamination. Lactitol is synthesized from lactose, and because of its chemical structure, it resists breakdown and absorption in the small intestine, a necessary feature for its therapeutic function in the colon.

The primary ingredient is a non-absorbable sugar derivative used for therapeutic benefit. This active component works without being absorbed into the body.

What is the General Therapeutic Purpose of Lactihep?

The general therapeutic purpose of Lactihep is to assist in the relief of constipation by promoting easier elimination and to provide support in managing conditions associated with elevated blood ammonia levels. The Lactitol component draws water into the colon through osmotic activity, effectively softening the stools and increasing their volume.

This supportive function is utilized in clinical scenarios where reducing circulating toxins is necessary, reflecting its secondary classification as an Ammonium Detoxicant. The mechanism of action for ammonia reduction involves the effect of unabsorbed disaccharides on colonic pH. This mechanism provides a non-systemic intervention for patients requiring assistance in toxin management.

Regulatory References

  1. Lactitol Drug Information

What side effects are possible with Lactihep?

Possible side effects and safety information

The safety profile for Lactihep (Lactitol Monohydrate) is primarily defined by the drug's localized action in the gastrointestinal tract, as documented in official regulatory sources like the EMA SmPC and FDA Prescribing Information.

Adverse Reaction Classification

Most adverse reactions fall under Gastrointestinal Disorders. These effects are categorized by frequency, reflecting their expected rate of occurrence in clinical use:

  • Very Common: Flatulence.
  • Common: Abdominal pain, abdominal discomfort, and Diarrhoea.
  • Uncommon: Nausea and Vomiting.

Serious Adverse Reactions and Safety Constraints

While most effects are localized and non-serious, the official profile includes documentation of serious potential consequences related to Metabolism and Nutrition Disorders. The primary serious risks include Dehydration and significant Electrolyte Disturbances, such as Hypokalaemia (low potassium) and Hypernatraemia (high sodium), particularly associated with excessive or prolonged use.

Specific Time-Related Patterns are noted: adverse reactions such as flatulence and abdominal discomfort are often most prominent at the initiation of therapy and tend to diminish with continued use.

Official regulatory documents define safety-related restrictions (Contraindications), which include conditions like Galactosaemia, Known or suspected mechanical intestinal obstruction, and pre-existing severe Fluid or Electrolyte Imbalances. For older adults and patients being treated for Hepatic Encephalopathy, specific monitoring of serum electrolytes is required during long-term therapy.

Overdose and Emergency Response

The official prescribing information for Lactihep (Lactitol Monohydrate) states that an overdose is primarily defined by the manifestation of severe gastrointestinal symptoms. Excessive dosage may result in pronounced abdominal pain and diarrhoea.

The resulting physiological risk documented in regulatory text is extensive fluid loss and subsequent electrolyte imbalance. Severe fluid loss can lead to dehydration and a critical depletion of potassium, known as hypopotassemia. This condition is documented as carrying a risk for the development of heart or neuromuscular dysfunction.

When Immediate Medical Help is Required

Immediate medical attention must be sought when symptoms indicate extensive fluid loss or severe electrolyte disturbances. The primary mandated emergency action is the cessation of treatment and the medical replacement of lost liquids and electrolytes to stabilize the patient and correct the imbalance.

Supportive Regulatory Guidance

No specific antidote is known for this product. Supportive treatment and symptomatic management are utilized. Furthermore, regulatory documents note that specific populations, such as the elderly or those in bad general condition, may be at increased risk of developing severe electrolyte disorders. For these groups, periodic monitoring of electrolyte levels is indicated following excessive exposure.

Therapeutic Uses of Lactihep

Lactihep is a prescribed solution primarily used to support the management of chronic constipation. It promotes relief by helping to achieve a more regular and comfortable bowel movement pattern. Its action can be a gentle option for individuals seeking sustained comfort.

It is also indicated for the management of certain symptoms associated with hepatic encephalopathy (HE). Use of the solution aims to support improvement in mental status and manage the cognitive effects associated with this condition, which occurs when the liver cannot efficiently process waste products. The primary conditions managed include chronic functional constipation and symptoms of hepatic encephalopathy.

Quick Fact: Relief for Constipation Lactihep works to encourage bowel movements, assisting in the long-term management of chronic constipation symptoms.

Eligibility and Restrictions for Use

Lactihep is contraindicated and must not be used by several specific patient populations, as defined by regulatory labeling. These absolute exclusions apply to individuals with the hereditary metabolic disorder galactosemia. Use is also strictly prohibited in patients with known or suspected mechanical obstruction of the gastrointestinal tract or gastrointestinal perforation. Furthermore, individuals with a known allergy or hypersensitivity to lactitol or its components are excluded.

The medicine is primarily established for adult patients. Its safety and efficacy have not been established in the pediatric population (children and adolescents), meaning its use is generally not recommended for this age group.

Conditional use is noted for specific comorbidities. Patients with diabetes mellitus or a pre-existing electrolyte imbalance are advised to use Lactihep with caution. Regarding physiological states, use during pregnancy is permitted only if clearly needed due to limited data, while it can generally be used during breastfeeding due to minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lactihep (Lactitol Monohydrate) exhibits a regulatory interaction profile primarily characterized by local action within the gastrointestinal tract and pharmacodynamic enhancement of fluid and electrolyte loss. Due to the minimal systemic absorption of the active ingredient, no severe or serious systemic metabolic interactions, such as those involving CYP enzymes or drug transporters, are formally documented in official prescribing information.

Pharmacokinetic Interactions (Local)

Lactitol may reduce the absorption of other oral medications if co-administered concurrently. This is a local pharmacokinetic effect where the presence of the syrup in the gastrointestinal tract interferes with drug uptake.

To mitigate this reduction in exposure, a mandatory timing rule applies: all other oral medicines must be administered at least 2 hours before or 2 hours after taking Lactihep to maintain their intended efficacy.

Pharmacodynamic Interactions

Co-administration with other laxatives may increase the severity of gastrointestinal adverse effects, such as the risk of excessive diarrhea. The use of certain substance classes alongside Lactihep can increase the risk of hypokalemia (low potassium levels) due to additive fluid and electrolyte loss. These substances include diuretics, corticosteroids, and Amphotericin B.

No specific restrictions regarding food or herbal products are universally documented in the product's regulatory labeling.

Mechanism of Action

The physiological actions of Lactihep are driven solely by its active ingredient, Lactitol Monohydrate, which operates through two non-systemic, complementary mechanisms within the digestive tract.

Modulation of Intraluminal Osmotic Fluid Dynamics

Lactitol is a non-absorbed osmotic agent that acts by establishing a concentration gradient in the colon. This mechanism drives the passive movement of water from the mucosal tissues into the intestinal lumen, increasing the volume and hydration of the faecal mass. The resulting physical distension of the colon stimulates smooth muscle contractions (peristalsis), leading to accelerated clearance of the bowel contents and a change in the consistency of the faecal mass.

Bacterial Metabolism and Toxin Ion Trapping

The second key domain involves the colonic microflora, which rapidly ferment Lactitol into short-chain organic acids (like lactic acid), thus lowering the colonic pH. This acidification is crucial as it facilitates the ionization of free ammonia ( NH3) into the non-absorbable ammonium ion ( NH4^+) . The NH4^+ ion is chemically trapped within the faecal mass and prevented from entering the systemic circulation, resulting in the faecal excretion of ammonium ion.

Dosage and Administration Information

How to Use Lactihep

Lactihep (Lactitol Monohydrate Oral Solution) is administered via the oral route for its intended actions within the digestive tract. The usage protocol is characterized by distinct, indication-specific dosing schedules that involve titration based on individual response.

Administration and Dosing Principles

The solution is generally taken once daily, although higher starting regimens may involve divided doses. For chronic constipation, the dose is often taken in the evening. The solution may be consumed with or without food and can be mixed with water or other suitable non-hot beverages to enhance intake, though excessive heat must be avoided as it may reduce efficacy. Accurate measurement is required, requiring the use of a calibrated device.

Indication Starting Dose Range (Lactitol) Maintenance Dose or Titration Goal
Chronic Constipation (Adults) 20 g to 30 g daily 10 g to 20 g daily
Hepatic Encephalopathy (HE) (Adults) 60 g to 70 g daily Adjust to achieve two to three soft stools per day

Usage Over Time and Specific Populations

Treatment is often characterized by long-term use for the management of chronic conditions, with the daily dose being adjusted (titrated) to achieve the defined therapeutic objective. Dosing for pediatric patients is weight-based, while dose modifications are generally not required for older adults based on age alone. Should a dose be missed, the protocol involves taking the dose as soon as it is remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose is skipped and the regular schedule resumed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lactihep

Lactihep, which contains Lactitol Monohydrate, has been the subject of research focused primarily on two distinct contexts: managing chronic constipation and addressing symptoms related to hepatic encephalopathy (HE). The evidence is primarily drawn from clinical studies, including Randomized Controlled Trials (RCTs) and comprehensive reviews that assess patterns of relief and systemic support. This section summarizes what research has explored and what findings have been described so far, based on scientific and regulatory documents.

Evidence for Use in Chronic Functional Constipation

The research base for using the active component in conditions marked by functional limitations like chronic constipation often involves short-term RCTs and systematic reviews. These studies primarily examined the changes in weekly bowel movement frequency and assessed stool characteristics, using patient-reported outcomes describing perceived discomfort or difficulty.

Studies monitored how symptoms evolved in the observed populations over defined time intervals, reporting various measurements related to the shift in bowel movement patterns. In these research contexts, some trials described that the measured changes in stool consistency were observed when the active component was used compared to using an inactive substance (placebo). Research examined the outcomes measured when the active component was compared to other commonly used osmotic laxatives. The overall data from these analyses form part of the broader evidence landscape for osmotic agents.

However, data are still emerging regarding the sustained use of the active component for constipation relief. The follow-up durations were limited in many primary trials, meaning there is limited information for long-term outcomes that fully characterize the durability of the observed patterns over many months.

Evidence for Use in Hepatic Encephalopathy (HE) Management and Prevention

The active component was studied for its utility in two main scenarios related to Hepatic Encephalopathy (HE), a condition characterized by systemic or functional imbalance related to liver function. These trials used outcomes monitoring physiological strain or stress, such as shifts in blood ammonia concentration, alongside assessments of patients' mental status.

HE Management: Trials for Acute Episodes

Research examined the use of the active component during episodes where symptoms become more noticeable or acute. Studies explored short-term symptom changes, evaluating the effect on clinical symptoms of HE and monitoring biochemical outcomes. Findings describe patterns observed in the studies related to the measured change in mental status and psychometric performance in the observed populations. Research provides insight into short-term changes, but the sample sizes were modest and the evidence quality varies across studies, particularly among older research designs.

HE Prevention: Prophylaxis and Recurrence Studies

The active component was evaluated in trials designed to prevent the recurrence of overt HE episodes in high-risk patients with cirrhosis. These studies focused on longer-term outcomes, such as tracking patterns related to the frequency of HE recurrence over intermediate-term periods. Evidence derived from these settings describes patterns related to how patients reported their experience and how conditions evolved, but certainty remains low for some of the secondary outcomes, and comparative evidence is lacking for many long-term endpoints.

Extended-Duration Research and Follow-up

Most of the definitive evidence, particularly for chronic constipation, is derived from studies with limited follow-up durations (often only a few weeks). This means that the evolution of symptoms over extended periods is not fully established by long-term clinical trials.

What Scientists Note as Uncertain or Limited

The scientific landscape highlights areas where research is still ongoing or where existing data have limitations. A key area of uncertainty is the lack of extensive, high-quality long-term outcomes research. Additionally, the evidence quality varies across studies, especially in the HE context, where methodological rigor was lower in some older publications. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Lactihep (FAQ)

Q: What is Lactihep used for?

A: Lactihep (Lactitol Monohydrate) is a synthetic sugar used primarily to treat constipation. It is a type of medicine known as a laxative.

It works by drawing water into the intestines, which softens the stool and makes it easier to pass. It is also sometimes used for a condition called hepatic encephalopathy, which is a decline in brain function that occurs in people with severe liver disease.

Q: How should I take Lactihep?

A: Lactihep is typically taken orally, usually once a day, and can be mixed with water or other suitable liquids or foods.

  • For Constipation: Follow the dosage instructions provided by your doctor. The dose may be adjusted based on your response.
  • For Hepatic Encephalopathy: The dosing is generally higher and aims for two to three soft stools daily. This treatment is closely monitored by a healthcare provider.

It is important to maintain adequate fluid intake while taking Lactihep.

Q: How long does Lactihep take to work?

A: The effect of Lactihep may not be immediate. It typically takes 24 to 48 hours (1 to 2 days) to produce a bowel movement.

Its action depends on it reaching the large intestine and being broken down by bacteria, which then draws water in. Do not take more than the recommended dose and be patient for the full effect.

Q: What are the common side effects of Lactihep?

A: As with many laxatives, the most common side effects of Lactihep are related to the digestive system. These may include:

  • Flatulence (gas)
  • Abdominal bloating or discomfort
  • Stomach cramps or pain
  • Diarrhea, especially at higher doses

These side effects are often mild and may decrease as your body adjusts to the medication. If side effects are persistent or severe, contact your healthcare provider.

Q: Can Lactihep be taken with other medications?

A: Lactihep may interact with certain other medications, which could affect how it works or increase the risk of side effects. It is important to inform your doctor or pharmacist about all the medications and supplements you are currently taking, including:

  • Other laxatives: Taking multiple laxatives may lead to severe diarrhea and dehydration.
  • Antacids: Some antacids may interfere with the effects of Lactihep.
  • Certain diuretics: There is a potential risk of electrolyte imbalance, particularly low potassium levels (hypokalemia).

Your healthcare provider can advise you on potential interactions and if any dosage adjustments are necessary.

How should Lactihep be stored and disposed of?

Official Storage and Disposal Requirements

Lactihep Oral Solution must be stored according to official regulatory labeling to ensure its stability. Mandatory storage conditions require that the syrup be kept below 30 C in a cool and dry place. It is essential to protect the solution from sunlight and excessive moisture.

Storage Restriction Requirement
Temperature Do not freeze
Container Keep tightly closed in the original container
Child Safety Keep out of the sight and reach of children

For disposal, unused or expired Lactihep must be handled strictly in accordance with local regulations. The medicine should not be poured into wastewater (such as drains or toilets) or placed into general household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lactihep found in:

A-Z Index: